Strumento inattivo

Altre lingue Acasti Pharma Inc Toronto S.E.

Azioni

APO

CA00430K1057

Prezzo di chiusura Toronto S.E. Altri mercati azionari
- ^CAD	-

27/06	Acasti Pharma Inc. annuncia il raggiungimento del 50% di arruolamento nello studio di sicurezza pivotale di Fase 3 STRIVE-On	CI
21/06	Acasti Pharma Inc. riporta i risultati degli utili per l'intero anno terminato il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial	27/06
Acasti Pharma Inc. Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-On Safety Trial	27/06
Acasti Pharma : Investor Presentation - June 2024	23/06
Acasti Announces Year-End 2024 Financial Results, Provides Business Update	21/06
Acasti Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	21/06
Acasti Pharma to Attend BIO International Convention 2024	28/05
Acasti Pharma Inc. to Attend BIO International Convention 2024	28/05
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights	12/02
Acasti: Fiscal Q3 Earnings Snapshot	12/02
Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12/02
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial	01/02
Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial	01/02
Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer	08/01
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024	13/12
Brain Hemorrhage Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	14/11
Acasti: Fiscal Q2 Earnings Snapshot	13/11
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights	13/11
Acasti Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	13/11
Aker BioMarine Gains Krill Assets from Acasti Pharma in $3.1 Million Settlement Deal	24/10/23
Aker BioMarine acquires patents, equipment, and scientific data from Acasti Pharma Inc	24/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Acasti Pharma Inc Toronto S.E.

Azioni

APO

CA00430K1057

Altre lingue

Filtri